CYP 517 (Uritact-EC 0.06 mg-81.6 mg-10.8 mg-36.2 mg)
Generic Name: hyoscyamine/methenamine/methylene blue/phenyl salicylate
Pill imprint CYP 517 has been identified as Uritact-EC 0.06 mg-81.6 mg-10.8 mg-36.2 mg.
Uritact-EC is used in the treatment of urinary tract infection and belongs to the drug class urinary antispasmodics. Risk cannot be ruled out during pregnancy. Uritact-EC 0.06 mg-81.6 mg-10.8 mg-36.2 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Generic Name:
- hyoscyamine/methenamine/methylene blue/phenyl salicylate
- CYP 517
- 0.06 mg-81.6 mg-10.8 mg-36.2 mg
- Prescription only
- Drug Class:
- Urinary antispasmodics
- Pregnancy Category:
- C - Risk cannot be ruled out
- CSA Schedule:
- Not a controlled drug
- Cypress Pharmaceutical Inc
More about Uritact-EC (hyoscyamine / methenamine / methylene blue / phenyl salicylate)
- Side Effects
- Dosage Information
- Drug Interactions
- Support Group
- 0 Reviews – Add your own review/rating
- Drug class: urinary antispasmodics
Related treatment guides
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2017 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.